NIKKEI 225
37,690.68 -769.40 (-2.00%) HANG SENG
17,263.81 +62.54 (+0.36%) CRUDE OIL
82.93 +0.12 (+0.14%) GOLD FUTURES
2,328.70 -9.70 (-0.41%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,452.13 -2,186.76 (-4.08%)
LAVA Therapeutics N.V. (LVTX)
After hours:
| Previous close | 2.9800 |
| Open | 2.9800 |
| Bid | 2.6900 x 100 |
| Ask | 2.8200 x 100 |
| Day's range | 2.7300 - 3.0100 |
| 52-week range | 1.1310 - 6.4700 |
| Volume | |
| Avg. volume | 1,158,362 |
| Market cap | 72.032M |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for EGFRd2 (PF-08046052/formerly LAVA-1223) LAVA 1266 tracking to Q2 2024 IND submission Strong balance sheet with cash of $95.6 million supports runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage
- Globe Newswire
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023UTRECHT, The Netherlands and PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Pfizer has achieved a clinical development milestone for PF-08046052 (formerly SGN-EGFRd2 /LAVA-1223), prompting the first milestone
- GlobeNewswire
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The Netherlands and PHILADELPHIA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), today announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its anti-PD-1 therapy KEYTRUDA® (pembr
